Across-Country Variations of Real-World Data and Evidence for Drugs: A 5-European-Country Study
- 25 January 2023
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 26 (4), 3-10
- https://doi.org/10.1016/j.jval.2023.01.009
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- How the United Kingdom Controls Pharmaceutical Prices and Spending: Learning From Its ExperienceInternational Journal of Health Services, 2021
- Risk sharing in managed entry agreements—A review of the Swedish experienceHealth Policy, 2020
- Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based studyThe Lancet Oncology, 2019
- Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial FibrillationStroke, 2019
- Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDSAmerican Journal of Cardiovascular Drugs, 2019
- Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA AgenciesPharmacoEconomics, 2017
- Value of treatment in clinical trials versus the real world: the case of abiraterone acetate (Zytiga) for postchemotherapy metastatic castration-resistant prostate cancer patients in SwedenScandinavian Journal of Urology, 2016
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationThe New England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009